000 04114nam a22005415i 4500
001 978-3-031-52197-3
003 DE-He213
005 20250516160026.0
007 cr nn 008mamaa
008 240424s2024 sz | s |||| 0|eng d
020 _a9783031521973
_9978-3-031-52197-3
050 4 _aRC321-580
072 7 _aPSAN
_2bicssc
072 7 _aSCI089000
_2bisacsh
072 7 _aPSAN
_2thema
082 0 4 _a612.8
_223
245 1 0 _aIon Channels as Targets in Drug Discovery
_h[electronic resource] /
_cedited by Gary Stephens, Edward Stevens.
250 _a1st ed. 2024.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2024.
300 _aIX, 537 p. 88 illus., 62 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aIon Channels as Targets in Drug Discovery: outlook and perspectives -- Conservation of ligand binding between voltage-gated sodium and T-type calcium channels -- The presynaptic α2δ protein family and their therapeutic potential -- Sodium channel in central hyperexcitability disease -- Therapeutic targeting of voltage-gated potassium channels -- The contribution of genetic sequencing information to the identification and functional characterisation of two pore domain (K2P) channels as viable therapeutic targets -- The voltage-gated potassium channel KV2.1 as a multicellular drug target -- Cystic fibrosis transmembrane conductance regulator (CFTR)-targeted therapeutics for cystic fibrosis -- Validation of TMEM16A modulation as a therapeutic approach for the treatment of cystic fibrosis - the discovery of novel TMEM16A potentiators -- Targeting acid-sensing ion channels in disease -- Transient Receptor Potential Canonical (TRPC) as a Therapeutic Drug Target -- Nicotinic receptors of the neuronal and non-neuronal cholinergic systems as therapeutic targets: Opportunities and limitations -- Purinergic P2X receptors as therapeutic targets -- Immune Cell Ion Channels as Therapeutic Targets -- Ion channel tools and therapeutics from venoms and toxins.
520 _aThis book is built around ion channel research and, more specifically, ion channels as important therapeutic drug targets. Under the editorial leadership of Gary Stephens in academic research and Edward Stevens from industry, the aim is to bring these strands together to provide a cutting-edge translational reference on ion channel drug discovery. Exploiting our knowledge of ion channel structure and function has clear current and future potential to intervene and correct the pathophysiology associated with debilitating conditions, including cardiovascular disease, diabetes, cystic fibrosis, pain, epilepsy, and neurodegenerative disorders. Individual chapters have a disease focus, also providing a "case study story" that will also appeal to a clinical audience, while background information on a given ion channel is presented to provide a solid reference for undergraduate and postgraduate teaching.
541 _fUABC ;
_cPerpetuidad
650 0 _aNeurosciences.
650 0 _aNeurochemistry.
650 0 _aPharmacology.
650 1 4 _aNeuroscience.
650 2 4 _aNeurochemistry.
650 2 4 _aPharmacology.
700 1 _aStephens, Gary.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aStevens, Edward.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031521966
776 0 8 _iPrinted edition:
_z9783031521980
776 0 8 _iPrinted edition:
_z9783031521997
856 4 0 _zLibro electrónico
_uhttp://libcon.rec.uabc.mx:2048/login?url=https://doi.org/10.1007/978-3-031-52197-3
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c274844
_d274843